Skip to main content

Table 7 Summary of multilvariate logistic regression model development

From: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Model Hospital Mortality Adjusted by Treatment and n Adjusted R2 Value Goodness of Fit Chi-square P value for Treatment Factor in Multivariate Model Odds Ratio,
Point Estimate (95% CI*)
Relative Risk Reduction
1 Propensity Quartiles 8806 0.034 0.002 0.0005 0.745
(0.631, 0.879)
15%
2 Age, Propensity Quartiles 8806 0.083 0.548 0.001 0.755
(0.638, 0.893)
14%
3 Age, 7 OD1 8939 0.159 0.073 0.0056 0.788
(0.665, 0.933)
13%
4 7 OD, Propensity Quartiles 8806 0.133 0.14 0.0002 0.722
(0.609, 0.857)
17%
5 Age, 7 OD, Propensity Quartiles 8806 0.161 0.258 0.0005 0.735
(0.618, 0.874)
16%
6 Age, 7 OD, Vasopressors, Propensity Quartiles 8806 0.190 0.178 0.0006 0.739
(0.622, 0.878)
16%
7 Age, 7 OD, Site of Infection, Propensity Quartiles 8806 0.173 0.68 0.0009 0.744
(0.625, 0.866)
15%
8 Age, 7 OD, Active Cancer Description, Propensity Quartiles 8806 0.170 0.821 0.0012 0.751
(0.631, 0.893)
15%
9 Age, 7 OD, Active Cancer, Propensity Quartiles 8408 0.167 0.952 0.0003 0.72
(0.603, 0.860)
17%
10 Age, 7 OD, Active Cancer, Source of Infection, Propensity Quartiles 8142 0.172 0.852 0.0002 0.712
(0.594, 0.854)
18%
11 Age, 7 OD, Active Cancer, Source of Infection, Vasopressors, Propensity Quartile 8142 0.200 0.131 0.0003 0.717
(0.598, 0.860)
18%
12 Age, 7 OD, Active Cancer, Vasopressors, Propensity Quartile 8408 0.197 0.278 0.0004 0.726
(0.607, 0.867)
18%
13 APACHE2 II Score, Propensity Quartiles 6431 0.162 0.658 0.0007 0.692
(0.559, 0.856)
18%
14 Imputed APACHE II Score, Propensity Quartiles 8806 0.128 0.956 <0.0001 0.71
(0.599, 0.843)
17%
15 Age, 7 OD, Imputed APACHE II Score, Propensity Quartiles 8806 0.198 0.765 0.0002 0.714
(0.599, 0.851)
18%
16 Age, 7 OD, Region3, Propensity Quartiles 8806 0.170 0.559 0.004 0.77
(0.644, 0.92)
14%
17 Age, 4 OD (no Cardiologic, Metabolic, Renal), Mechanical Ventilation, Renal Replacement Therapy, Platelet Transfusion, Enteral Nutrition, Mechanical-VTE-Prophylaxis, LMWH, Active Cancer, Propensity Quartiles 8283 0.278 0.028 0.0115 0.783
(0.647, 0.947)
13%
  1. * 95% Confidence Intervals (CI).
  2. See Additional data file 1 for additional detail of propensity score methodology. Propensity quartiles represent subgroups in which the probability of receiving drotrecogin alfa (activated) was roughly constant. Imbalances in unobserved variables have not been accounted for as they would be in a randomized trial.
  3. 1 Organ Dysfunctions (OD).
  4. 2 Acute Physiology And Chronic Health Evaluation. APACHE II scores were missing for over 3300 patients. In models that include APACHE II score imputed, these missing values were imputed with the overall mean APACHE II score.
  5. 3 Active Cancer Description had several categories (e.g. hematologic, solid tumor etc.), while Active Cancer was categorical (i.e. Yes/No).
  6. 4 Region represents Europe, US/Canada, and Other.
  7. LMWH = low molecular weight heparin; VTE = venous thromboembolism.